-
公开(公告)号：KR1020140026207A
公开(公告)日：2014-03-05
申请号：KR1020120093322
申请日：2012-08-24
Applicant: 성균관대학교산학협력단
Abstract: The present invention relates to microorganisms for producing hexanol which activation of cytochrome P450 monooxygenase is enhanced and a microorganism producing method. Also, the present invention relates to a hexanol production method comprising a step of culturing the microorganisms; and a step of collecting hexanol from the cultures or microorganisms and hexanol produced therefrom. According to the present invention, an existing 1-hexanol production method has low production in spite of long-time fermentation thereby blocking an biosynthesis industry of 1-hexanol, however, as genes presented in the present invention are introduced, microorganisms which have been significantly advanced in fermentation time and production volume are provided. Accordingly, when using microorganisms, it is believed to significantly contribute to 1-hexanol bio synthesis and the growth of a bio-plastic industry and is helpful for a simple and low-cost bio-plastic production method.
Abstract translation: 本发明涉及细胞色素P450单加氧酶的活化增强的微生物和微生物的制造方法。 此外，本发明涉及包含培养微生物的步骤的己醇生产方法; 以及从培养物或微生物和由其制备的己醇收集己醇的步骤。 根据本发明，尽管长时间发酵，现有的1-己醇生产方法生产量低，从而阻断了1-己醇的生物合成工业，但是，如本发明所述的基因被引入，已经显着地显示了微生物 提供发酵时间和生产量先进。 因此，当使用微生物时，据信对生物塑料工业的1-己醇生物合成和生长有显着贡献，有助于简单且低成本的生物塑料生产方法。
-
公开(公告)号：KR1020140022261A
公开(公告)日：2014-02-24
申请号：KR1020120088641
申请日：2012-08-13
Applicant: 성균관대학교산학협력단
Abstract: The present invention relates to a method for screening an antiallergic substance by confirming the inhibition of a soluble NSF attachment protein receptor involved in degranulation of mast cells. According to the present invention, the method can be used for improvement of allergic diseases and the development of a therapeutic substance by screening an antiallergic substance and enables more effective studies on the mechanism of allergy based on the results confirmed by the present invention.
Abstract translation: 本发明涉及通过确认参与肥大细胞脱颗粒的可溶性NSF附着蛋白受体的抑制来筛选抗过敏物质的方法。 根据本发明，该方法可以通过筛选抗过敏物质来改善过敏性疾病和治疗物质的发展，并且能够基于本发明确认的结果，更有效地研究过敏机理。
-
公开(公告)号：KR101293777B1
公开(公告)日：2013-08-06
申请号：KR1020100062610
申请日：2010-06-30
Applicant: 성균관대학교산학협력단
Abstract: 본 발명은 서열번호 1 내지 서열번호 3으로 이루어진 군으로부터 선택되는 펩타이드에 관한 것이다. 또한 본 발명은 상기 펩타이드를 코딩하는 폴리뉴클레오티드, 상기 폴리뉴클레오티드를 포함하는 벡터 및 상기 벡터를 보유하는 숙주세포에 관한 것이다. 또한 본 발명은 상기 펩타이드를 유효성분으로 포함하는 알러지성 질환 치료 및 예방용 조성물 및 화장료 조성물에 관한 것이다. 또한 본 발명은 서열번호 1 내지 서열번호 3으로 이루어진 군으로부터 선택되는 펩타이드의 치료학적 유효량을 포함하는, 인간을 제외한 개체의 알러지성 질환을 치료 또는 예방하는 방법에 관한 것이다.
Abstract translation: 本发明涉及选自SEQ ID NO：1至SEQ ID NO：1的肽。 本发明还涉及编码所述肽的多核苷酸，包含所述多核苷酸的载体和携带所述载体的宿主细胞。 本发明还涉及用于治疗和预防过敏性疾病的组合物和包含该肽作为活性成分的化妆品组合物。 本发明还涉及治疗或预防个体以外的个体的变应性疾病的方法，其包含治疗有效量的选自SEQ ID NO：1至SEQ ID NO：1的肽。
-
公开(公告)号：KR1020130085923A
公开(公告)日：2013-07-30
申请号：KR1020120125518
申请日：2012-11-07
Applicant: 성균관대학교산학협력단
IPC: A61K47/48 , A61K47/42 , C07K17/14 , C07K14/775
CPC classification number: A61K47/42 , A61K9/1075 , A61K31/337 , A61K31/427 , A61K31/44 , A61K31/4412 , A61K31/519 , A61K31/704 , A61K39/02 , A61K47/50 , C07K14/775 , C07K17/14
Abstract: PURPOSE: A high intensity lipoprotein (HDL) - analogous particle combination is provided to be able to be widely used for the development of the drug specific target. CONSTITUTION: A high intensity lipoprotein (HDL) - analogous particle combination comprises apolipoprotein A- I (apoA-I) and drug, The drug which the pH is dependently sampled can be ejected. The apolipoprotein A- I (apoA-I) comprises the amino acid sequence of the sequence number 1. Drug comprises the ring structure. It is selected from group comprised of the drug is the paclitaxel, DX (doxorubicin), MTX (methotrexate), SF (Sorafenib) and EpoB (Epothilone B).
Abstract translation: 目的：提供高强度脂蛋白（HDL） - 类似颗粒组合，以便能够广泛用于药物特异性靶标的开发。 构成：高密度脂蛋白（HDL） - 类似颗粒组合包含载脂蛋白A-I（apoA-I）和药物，可以排出pH值依赖性取样的药物。 载脂蛋白A-I（apoA-I）包含序列号1的氨基酸序列。药物包含环结构。 选自紫杉醇，DX（多柔比星），MTX（甲氨蝶呤），SF（索拉非尼）和EpoB（Epothilone B）药物组。
-
Patent Agency Ranking
公开(公告)号：KR1020130001121A
公开(公告)日：2013-01-03
申请号：KR1020120061819
申请日：2012-06-08
Applicant: 삼성전자주식회사 , 성균관대학교산학협력단
Abstract: PURPOSE: A modified microorganism for producing lactic acids and a method for producing lactic acids are provided to produce lactic acids with high efficiency under an acidic condition. CONSTITUTION: A modified microorganism for producing lactic acids with high efficiency has LDH activity of Pelodiscus sinensis japonicus, Ornithorhynchus anatinus, Tursiops truncates, and Rattus norvegicus. The modified microorganism is yeast or bacteria. The modified microorganism is E.coli or Kluyveromyces marxianus. The modified microorganism produces lactic acids with 12.2% or more of glucose. An expression vector for producing the modified microorganism comprises: a replication origin; a promoter; a polynucleotide; and a terminator. A method for producing lactic acids comprises: a step of culturing the modified microorganism in a medium containing glucose; and a step of collecting lactic acids from the culture.
Abstract translation: 目的：提供用于生产乳酸的改性微生物和生产乳酸的方法，以在酸性条件下高效生产乳酸。 构成：用于高效生产乳酸的改良微生物具有日本芍药，鸟腥草，Tur ps属，and and属的LDH活性。 修饰的微生物是酵母或细菌。 修饰的微生物是大肠杆菌或马克斯克鲁维酵母（Kluyveromyces marxianus）。 经修饰的微生物产生具有12.2％或更多葡萄糖的乳酸。 用于产生修饰微生物的表达载体包括：复制起点; 启动子 多核苷酸; 和终结者。 制备乳酸的方法包括：在含有葡萄糖的培养基中培养经修饰的微生物的步骤; 以及从培养物中收集乳酸的步骤。
-
公开(公告)号：KR1020130001103A
公开(公告)日：2013-01-03
申请号：KR1020110139520
申请日：2011-12-21
Applicant: 삼성전자주식회사 , 성균관대학교산학협력단
Abstract: PURPOSE: A modified microorganism for producing lactic acids is provided to prepare lactic acids with high efficiency under an acidic condition. CONSTITUTION: A modified microorganism for producing lactic acids has a lactate dehydrogenase(LDH) activity of Pelodiscus sinensis japonicus, Ornithorhynchus anatinus, Tursiops truncates, or Rattus norvegicus. The modified microorganism is Escherichia sp. or Kluyveromyces sp. The modified microorganism produces lactic acids with 34% or more of glucose. An expression vector contains: a replication origin for constructing the modified microroganisms; a promoter; a polynucleotide coding LDH activation of one or more species selected from the group consisting of Pelodiscus sinensis japonicus, Ornithorhynchus anatinus, Tursiops truncates, or Rattus norvegicus; and a terminator. The replication origin is ARS/CEN replication origin.
Abstract translation: 目的：提供一种用于生产乳酸的改性微生物，用于在酸性条件下高效制备乳酸。 构成：用于生产乳酸的改良微生物具有日本芍药（Ornisorhynchus anatinus，Tursiops truncates）或褐藻（Rattus norvegicus）的乳酸脱氢酶（LDH）活性。 修饰的微生物是大肠杆菌属 或克鲁维酵母属 经修饰的微生物产生具有34％以上葡萄糖的乳酸。 表达载体包含：用于构建修饰的微结构的复制起点; 启动子 编码一种或多种选自以下的物质的LDH活化的多核苷酸：日本Pe us，鸟，us us us，，，;;;;;;;;;;;;;;;;;; 和终结者。 复制起点是ARS / CEN复制来源。
-
公开(公告)号：KR1020130000883A
公开(公告)日：2013-01-03
申请号：KR1020110061677
申请日：2011-06-24
Applicant: 삼성전자주식회사 , 성균관대학교산학협력단
CPC classification number: C12N15/815 , C12P21/00 , C12P21/02
Abstract: PURPOSE: An expression vector which overexpresses target proteins, and a method for producing the target protein are provided to obtain the proteins in K. marxianus. CONSTITUTION: An expression vector contains: a replication origin; a CYC promoter, a TEF promoter, a GPD promoter, or an ADH promoter; and a terminator. The CYC promoter contains a sequence of sequence number 1 or a sequence having 70% or more sequence homology with the sequence of sequence number 1. The TEF promoter has a sequence of sequence number 2 or a sequence with 70% or more sequence homology with the sequence of sequence number 2. GPD promoter contains a sequence of sequence number 3 or a sequence having 70% or more homology with the sequence of sequence number 3. The ADH promoter has a sequence of sequence number 4 or a sequence having 70% or more sequence homology with the sequence of sequence number 4.
Abstract translation: 目的：提供过表达靶蛋白的表达载体和产生靶蛋白的方法，以获得马克斯马氏霉属中的蛋白质。 构成：表达载体包含：复制起点; CYC启动子，TEF启动子，GPD启动子或ADH启动子; 和终结者。 CYC启动子含有序列号1的序列或与序列号1的序列具有70％以上序列同源性的序列.TEF启动子具有序列号2的序列或具有70％以上序列同源性的序列 序列号2的序列.GPD启动子含有序列号3的序列或与序列号3的序列具有70％以上同源性的序列.ADH启动子具有序列号4的序列或70％以上的序列 与序列号4的序列同源性。
-
公开(公告)号：KR1020120001964A
公开(公告)日：2012-01-05
申请号：KR1020100062610
申请日：2010-06-30
Applicant: 성균관대학교산학협력단
Abstract: PURPOSE: A peptide for preventing and treating allergic diseases and a composition containing the same are provided to suppress degranulation of mast cells. CONSTITUTION: A peptide for treating and preventing allergic diseases contains an amino acid sequence selected from sequence numbers 1-3. A composition for preventing and treating allergic diseases contains the peptide as an active ingredient. The allergic diseases include anaphylaxis, allergic rhinitis, asthma, urticaria, atopic dermatitis, contact dermatitis, or allergic dermatitis. The composition additionally contains PTD(protein transduction domain). A cosmetic composition for treating or preventing allergy contains the peptide as an active ingredient.
Abstract translation: 目的：提供用于预防和治疗过敏性疾病的肽以及含有该肽的组合物以抑制肥大细胞的脱粒。 构成：用于治疗和预防过敏性疾病的肽含有选自序列号1-3的氨基酸序列。 用于预防和治疗过敏性疾病的组合物含有肽作为活性成分。 过敏性疾病包括过敏反应，过敏性鼻炎，哮喘，荨麻疹，特应性皮炎，接触性皮炎或过敏性皮炎。 该组合物另外含有PTD（蛋白质转导结构域）。 用于治疗或预防过敏的化妆品组合物含有肽作为活性成分。
-
公开(公告)号：KR1020090041066A
公开(公告)日：2009-04-28
申请号：KR1020070106584
申请日：2007-10-23
Applicant: 성균관대학교산학협력단
IPC: C07K7/00
Abstract: A synthetic peptide which is similar to a kernel composite of SNARE(Soluble ethylmaleimide-sensitive factor attachment protein) is provided to control a neutrotransmitter release by hindering the formation of SNARE composite and to ensure the control of the intercellular reaction, improvement of skin wrinkle and pain relieving effects. A peptide fragment controlling a neutrotransmitter release by suppressing the formation of SNARE composite is the whole(SEQ ID NO:2) of peptides configuring N-end part of the core domain of syntaxin 1a protein forming the SNARE composite or a part of peptides; the whole(SEQ ID NO:4) of peptides configuring N-end part of C-helix of SNAP-25 forming the SNARE composite or a part of peptides; and the whole(SEQ ID NO:8) of peptides configuring N-end part of core domain from VAMP-2 protein forming the SNARE composite or a part of peptides.
Abstract translation: 提供类似于SNARE（可溶性乙基马来酰亚胺敏感因子附着蛋白）的核复合物的合成肽，以通过阻碍SNARE复合物的形成来控制中性转运体释放，并确保控制细胞间反应，改善皮肤皱纹和 止痛效果。 通过抑制SNARE复合物的形成来控制中性转运体释放的肽片段是构成形成SNARE复合物或部分肽的syntaxin 1a蛋白的核心结构域的N末端部分的肽的整个（SEQ ID NO：2） 构成形成SNARE复合物或部分肽的SNAP-25的C-螺旋的N末端的肽的整个（SEQ ID NO：4） 和形成SNARE复合物的VAMP-2蛋白的核结构域的N末端部分的肽的全部（SEQ ID NO：8）或肽的一部分。
-
-
-
-
-
-
-
-
Search Results
59
records
(took 0.033 seconds)
